Open in interactive viewer → charts, metric popovers & call review

BICO Buries Its Lab Automation Ambition Just as the Numbers Need a New Story

A SEK 296m Biosero write-down and a one-off SCIENION licence deal turn Q3 into a reset quarter — precision biology is the new pitch.
BICO.ST · Earnings Call · 2026-11-11

The reset is the story

Anders Fogelberg's first call as CEO was never going to be a routine quarter. He used it to launch BICO 2030, a strategy that explicitly narrows the company to precision biology — cell handling, culture and analysis — and away from the large customised lab-automation projects that had been the group's strategic centrepiece. The language is unusually blunt for a CEO launch: “Large-scale integrated lab automation projects will no longer be a core focus. We are assessing strategic options for Biosero...” — Anders Fogelberg, President and CEO · 2026-11-11 That is not a tweak. It is a reversal of the BICO 2.0 story that previous management sold for several years. The old story was Lab Automation as the scalable growth engine. In April 2025, Maria Forss told analysts: “There is a continued strong underlying demand in Lab Automation.” — Maria Forss, President and CEO · 2025-04-29 Even in August 2026, Anders himself was still talking about reassessing the space rather than exiting it: “we are reassessing this space. What does this mean for us? How can we scale this in a good way?” — Anders Fogelberg, President and CEO · 2026-08-19 Three months later the answer is a SEK 296m impairment against Biosero's goodwill and technology and a formal process to assess strategic options. The large scale integrated lab automation project business is now a problem to be managed, not a platform to be scaled.

The quarter: a flattering optical result

The headline looks strong: net sales of SEK 465m, up 20% quarter-on-quarter and 19% organically, with adjusted EBITDA of SEK 124m and a 27% margin. But the quality of that number is doing a lot of work. The SCIENION agreement — extended supply and licence deals with a diagnostics customer — contributed SEK 135m in the quarter, including SEK 83m of upfront licence revenue for a five-year non-cancellable period. Excluding those agreements, sales declined; instrument sales fell 11% because the prior-year quarter had a large Biosero project start. The genuine underlying signal is narrower: instrument sales in BICO's own benchtop range grew 14% and consumables grew 5%. Ewa Linsater was refreshingly direct about the distortion: “The reported profitability is exceptionally strong and includes a significant contribution from the SCIENION agreements. We, therefore, don't view the Q3 margin as a representative of a normal quarterly run rate.” — Ewa Linsater, Group CFO · 2026-11-11 Cash flow from operating activities was negative SEK 41m, mainly because revenue was recognised upfront while cash arrives over the contract term, and working capital rose to around 50% of rolling 12-month sales. The group still ended with SEK 555m of cash and a net cash position of SEK 124m, so this is not a liquidity scare. It is an earnings-quality story.

Following the assessment, we recognized an impairment of approximately SEK 296 million against Biosero's remaining goodwill and technology. This is a noncash charge with no effect on liquidity or covenants.

Ewa Linsater, Group CFO · 2026-11-11

What management stopped saying

The most telling part of the call is what disappeared. For several quarters, Biosero and lab automation dominated the keyword record: Lab Automation was a top-ranked theme in 2024 and 2025, and management kept promising a more efficient cost base and better project execution. On this call, Biosero is discussed mainly as an impairment, a drag on working capital and a candidate for strategic alternatives. The new vocabulary is new strategy, cash generation and accountability. That is a classic post-writedown reset: the strategy document changes because the old capital allocation did not work. The targets have not changed — double-digit organic growth, an EBITDA margin above 10% after capitalised development, and net debt/EBITDA below 3x — but the route to them has. Anders was careful to avoid forward guidance while still trying to sound confident: “We don't give forecasts, but I can say that the purpose of the new strategy is to give us the best conditions possible to consistently reach our financial targets.” — Anders Fogelberg, President and CEO · 2026-11-11 Investors have heard that construction before. The difference is that this version comes with a write-down and an explicit admission that Biosero did not develop as expected.

The market is not the main variable

Management's market commentary is cautiously better but not new. Pharma and biotech demand has improved, diagnostics is okay, and the academic segment remains the weak spot. Anders explained that NIH funding is coming back but favouring larger projects, which helps specialised equipment and hurts more commodity-like products. That is essentially the same academic-headwind story BICO has told for multiple quarters, including in February 2026 and August 2026. It is a real headwind, but it is not the reason for the reset. The reason is that the large-project automation model consumed capital and management attention without delivering the promised scalable growth. The AI angle is more interesting, and more credible than the old automation pitch. Anders argued that AI accelerates discovery upstream but pushes the bottleneck into the wet lab, where biological material still has to be handled, cultured and analysed. That is a genuine industry theme, and it fits the precision-biology language now running through BICO's narrative. But it also raises the bar: if AI is the demand driver, BICO needs instruments and software that are agent-ready, not custom integration projects built on third-party hardware. The new CTO hire and the talk of AI-enabled microscopes and UP.SIGHT are early steps; they are not yet proof.

Why it matters

BICO is a small-cap medical-devices name with a market capitalisation of roughly SEK 116m-equivalent, so the share price can move on narrative alone. The narrative just changed materially. The company is asking investors to believe in a narrower, higher-quality precision-biology portfolio while it absorbs a SEK 296m non-cash write-down, carries elevated working capital and admits that Q3 profitability was flattered by a one-off licence deal. The old long-term targets have been reconfirmed, but the path to them now runs through businesses that were previously side acts. The bull case is that BICO's benchtop instruments and consumables are genuinely differentiated and growing, and that shedding the large-project business removes a source of volatility and cash burn. The bear case is that the core business is not yet big enough to carry the group's cost base, and that the SCIENION deal masks a softer underlying quarter. The next catalyst is the 25 November strategy deep dive, where management must show numbers behind the rhetoric. For now, the honest read is that BICO has finally stopped defending a strategy that was not working. That is a necessary first step, but it is not yet a proven turnaround.